Acumen Pharmaceuticals CEO Discusses Novel Targeted
The Race Against Alzheimer’s: Emerging Therapies and Future Trends Alzheimer’s disease affects over 55 million people globally, presenting a significant challenge for healthcare systems and society. A promising frontier in this battle is the development of targeted therapeutics, such as those pioneered by Acumen Pharmaceuticals. By focusing on sabirnetug, a monoclonal antibody that targets amyloid … Read more